CLEC4C

CLEC4C

CLEC4C Overview

Molecule Name
C-Type lectin domain family 4 member C
Synonyms
DLEC,CLEC4C,BDCA-2,CD303,CLECSF11,CLECSF7, HECL
Drug Development Progress
Drugs in Clinical Trials9
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
DLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Background
CLEC4C (C-type lectin domain family 4 member C), also known as BDCA2, CLECSF11, CLECSF7, DLEC and CD303. Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cell. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binds to serum IgG. Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells. May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium.

CLEC4C Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
LitifilimabBIIB-059Phase 3 ClinicalBiogen Inc
Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
SSGJ-626SSGJ-626; 626Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
DB-2304DB-2304Phase 2 ClinicalDuality Biologics (Suzhou) Co Ltd
Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
ANB-101CBS-004; ANB101Phase 1 ClinicalCapella Bioscience Ltd
Inflammation; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Scleroderma, Systemic
Details
BCD-256BCD-256Phase 1 ClinicalBIOCAD JSC
Lupus Erythematosus, Systemic
Details
GB-19GB-19; GB19Phase 1 ClinicalShandong Kexing Bio-Products Co Ltd
Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
Recombinant anti-BDCA2 humanized monoclonal antibody (Sansheng Guojian)Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
HC-022HC-022; HC022Phase 1 ClinicalShanghai Hongcheng Pharmaceutical Co Ltd
Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic
Details
LBL-047DNTH-212; LBL-047; DNTH212Phase 1 ClinicalNanjing Leadsbiolabs Co Ltd
Autoimmune Diseases; Lupus Erythematosus, Systemic
Details